Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O9JZ
|
|||
| Drug Name |
PMID26560530-Compound-49
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
University of Texas
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H14ClFN6O2S
|
|||
| Canonical SMILES |
CC(=O)NC1=CC(=CC=C1)N2N=C(N=N2)SCC(=O)NC3=CC(=C(C=C3)F)Cl
|
|||
| InChI |
1S/C17H14ClFN6O2S/c1-10(26)20-11-3-2-4-13(7-11)25-23-17(22-24-25)28-9-16(27)21-12-5-6-15(19)14(18)8-12/h2-8H,9H2,1H3,(H,20,26)(H,21,27)
|
|||
| InChIKey |
NIWRZNPQACMKRY-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue transglutaminase (TG2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tissue transglutaminase (TG2) | Target's Patent Info | [1] | |
| KEGG Pathway | Huntington's disease | |||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Thromboxane A2 receptor signaling | ||||
| Alpha9 beta1 integrin signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.